NEW YORK, March 28 - Friz Biochem of
Existing shareholder Global Life Science Ventures led the round, joined by DRF Beteiligungsgesellschaft as a co-investor.
The company expects to raise additional funds, including soft loans, in a second closing.
Friz develops a DNA microarray platform with an electrical readout technology. It plans to use the funding to establish pilot production capabilities and to validate the arrays in the areas of food pathogens and clinical diagnosis.
For further information, see the company statement.